focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
A large sell being worked, look out for delayed trades?
Morning draft. Perhaps we aren't going to be this size for very long. News flow expectations.
Chief Financial Officer and new director appointment quickly follows CEO appointment. Significant increase in costs for tiny company, must be expecting growth in revenues. Commercial deals in clinical sphere expected.
I think Trevor Brown adding to holding may be significant. His development of Stone checker under the Flying Brands ticker is gaining traction and the Chief Technical Officer is Balaji Ganeshan who is also an executive director at Texrad under the Feedback ticker. Balaji was the founder and developer of Texrad software and the relationship with Trevor is close. Information will undoubtedly be shared and I don't believe Trevor would be investing again without some degree of confidence in both the new CEO at Feedback and expectations of positive delivery of news in clinical sector.
Hi mate, how bizarre is this! Perhaps a truce has been called and he knows something. Next he'll want his seat back on board. Don't know what to make of it do you?
is back today. Good to see confidence returning.
Yes, as part of licencing out Texrad to Stonechecker we receive % of revenues, not sure the level. Nick Stephens spoke well and confirmed that although they have a small team they have the resources to achieve milestones which are clearly laid out. They have achieved much ahead of schedule and he commented that AI is all the talk in radiology community. Come on Texrad let's do it!
Most potential investors have been put off with Trevor Brown's overhang and regular sales. I wonder why someone has the confidence to invest �30k at this moment? Extremely promising.
Someone has a bit, 1 million buy for �13.9k! You Botak?!!
Love it! Let's get rid of those Cherokees asap....
Hi Tobriand, not much discussion here I agree but long term holders have approached company seeking some meat on the bones thrown out in today's interims. I think we now acknowledge that progress has been as much as could be expected for such a tiny company with limited resources. The company have addressed this to some degree with the recent CEO appointment. I know you had issues about lack of leadership and Mr Crabb as CEO certainly should overcome this. I also acknowledge your views on cash burn, although second half revenue is expected to be higher. Can I throw something out there, is there a resistance in the radiology community to AI? It requires significant changes in the way they look at scan results and software ie. Texrad must be 100% foolproof. There is a huge difference between using it for research to using it to make patient care decisions which affect outcomes. Your thoughts appreciated.
A little long suffering yes but always open to polite discussion and debate. I sense a touch of scepticism on progress Tobriand and hope politely that you are wrong! The equity raise was for specific purpose and like Bob would expect some detail on product development progress, Alliance Medical deals and alliances with global manufacturers of scanners etc. If cash burn has been to make real progress in these areas I think long term holders will be 're assured.
Steady buying last days into interim, due in a few days, a few expecting positive news, also moving above 50MA.
Hi Bob, likewise I share your optimism. I confess to even being a little excited at what David Crabb will bring to our company. To have a full time CEO which is long overdue will place his hand firmly on the tiller and expect some real positive announcements over the next few months. As Tom Charlton said recently it's a "key moment for Texrad". Good luck all shareholders.
Not me profit, I'm a long term holder, been here years!
Bought Wednesday @ 1.6 sold today for 1.67, profit �440, I suppose if you do that type of trade every week you're not complaining.
Hi Bob and Adrianz, in addition to the major points mentioned in 1535 post, Equity raise of �750k nearly a year ago, for sales and marketing and product development, 1. What sales streams have/are being developed in which regions globally, revenues expectations please, 2. Product development, specifically what products being developed in house, with Future Processing and progress with Quibim for Prostate Cancer. 3. What are milestone during next period especially the use of Texrad in clinical environments. 4. When can we expect future CE Mark for additional products? Currently all use of Texrad software is in research and until first adoption clinically I think will continue to struggle to convince market, over to you Mr Crabb.
Thanks Botak, very interesting article. As a word of caution, adoption by radiologists in clinical settings is vital, seen a few comments in Aunt Minnie journal about some resistance to new technologies. They have been examining scans in the same way (without AI) for such a long time, powers of persuasion by AI providers needs to be absolutely foolproof. We're getting there, today's appointment is important and market response positive. Nice feeling today!! Take care.
Morning all, good to see appointment has triggered some early buys. Full time leader has been required for months now and I expect some positive news going forward. Mr Crabb will have carried out due diligence before accepting post so I believe the appointment to be very good news. Good luck all.
Evening all. Always disappointed when these guys come to market for cash but I think it might be slightly different this time; it's for a minimal amount compared with previous placing and Director participation is rare. It will be interesting to see if Ian Hallett, the new majority shareholder @20% took part in the placing as I think he is key to the future. The increase in recurring revenues is a big plus and they do seem to be making progress. Interesting to see how material business develops.